Remove Invention Remove Marketing Remove Patent Remove Public Use
article thumbnail

“Prior public use”: an effective ground for opposition against the grant of a European patent

Garrigues Blog

The opposition procedure for European patents, enables third parties, within nine months of the publication of the mention of the grant of the patent, to oppose that patent at the European Patent Office (EPO). One of the most effective ways of obtaining the revocation is to prove “prior public use”.

article thumbnail

Empowering Innovation: The Role of Intellectual Property in Technology Transfer

IP and Legal Filings

Its gained momentum with the advent of importance in R&D and patent registration. It’s the first important step towards protecting owner’s rights and its lawful public use. If IPR is not understood in technology transfer process, sharing of knowledge and invention faces legal challenges. It helps in better valuation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Prior Art: The Patent Pitfall

Larson & Larson

A high number of patent applications are given a non-final rejection from the USPTO according to Yale. Often, the reason that the patent office will cite for rejecting an application is the presence of prior art. You may have heard the term ‘prior art’ before in the context of patents. What is Prior Art?

Art 52
article thumbnail

Understanding Compulsory Licensing and Access to Essentials

Kashishipr

A compulsory license is an authorization provided by a national authority to an individual without seeking the consent of the titleholder but after payment of royalties/compensation for the exploitation of the subject matter protected by the law on patents or other IPRs.

Licensing 105
article thumbnail

The US’ Review of March-in Rights, and Some Questions on an Indian Counterpart

SpicyIP

It seems that the domestic pressure resulting from their ever-increasing healthcare costs has reached a point where there is finally some re-examination of how their patent system is affecting costs. According to the NIST, the US govt invests approximately $115 billion in R&D through various universities, non-profits, and businesses.

article thumbnail

“What’s Mine Is Not Yours To Give Me”—Nor To Take Without Just Compensation: A New Jersey’s Reaction To Sovereign Immunity, Intellectual Property, & Takings

LexBlog IP

And, it goes like this–the relevant concept in the United States is that a person shall “ no[t] be deprived of life, liberty, or property, without due process of law; nor shall private property be taken for public use, without just compensation.” 14 Landslide 30 (No. Wright , 94 U.S. ”); James v. 2d 480 (Fed.

article thumbnail

Biosimilars 2020 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

At the same time, market uptake of biosimilars in the United States continued to increase, suggesting that there is room for expansion of biosimilars in the U.S. In addition, fewer new biosimilars entered the market this past year, with five biosimilar launches in 2020 as compared to seven in 2019. Yet biosimilars of anti-TNF?